The Life Sciences team advised Amylyx Pharmaceuticals, Inc. on its upsized initial public offering of 10,000,000 shares of common stock at an initial public offering price of $19.00 per share. All of the shares were offered by Amylyx. The gross proceeds to Amylyx from this offering, prior to any exercise of the underwriters’ option to purchase additional shares, were $190 million, before deducting underwriting discounts and commissions and offering expenses.
Amylyx’ common stock began trading on the Nasdaq Global Select Market under the ticker symbol "AMLX" on January 7, 2022, and the offering closed on January 11, 2022. Amylyx’ lead candidate, AMX0035, currently has marketing applications pending in Canada, the United States, and Europe for the treatment of Amyotrophic Lateral Sclerosis.
The Goodwin team was led by Mitch Bloom, Ben Marsh, Nirali Shah, Tom Schaad, Meg Dennard and Larissa Pinho (Corporate) and Julie Tibbets and Emily Tribulski (FDA Regulatory), and included Sabrina Poulos (IP), Roger Cohen and Heath Ingram (Healthcare), Dan Karelitz and Leon Peschel (Tax), Natascha George, James Devendorf and Jeremy Slotnick (Executive Compensation), Christina Lewis and Lee Douthitt (Labor & Employment), Brad Weber (Opinions) and with invaluable assistance from Sarah Bock, Pam Finan and Tricia Hojo.
For additional details on the offering, please read the press release.